Back to Search

A Phase 2 Evaluation of the Safety and Efficacy of AL8326 in >=2nd Line Small Cell Lung Cancer (SCLC) Treatment

  • Protocol Number: 202207103
  • Principal Investigator: Waqar, Saiama
  • Cancer Types: Lung

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients who need >=2nd line treatment .

Protocol Interventions

AL8326 low dose group, AL8326 middle dose group, AL8326 high dose group